(Total Views: 248)
Posted On: 06/26/2020 6:10:26 PM
Post# of 281
NetworkNewsBreaks - Predictive Oncology Inc. (NASDAQ: POAI) Subsidiary Leverages Unique Patient-Derived Platform to Assist Oncologists
Predictive Oncology (NASDAQ: POAI), through its Helomics subsidiary, is providing clinical decision support tools to support oncologists in personalizing cancer treatment. A recent article discussing the company further reads, “Through its unique patient derived (PDx) platform, which tests the drug response and biomarker profile of the patient’s own tumor, and its vast database of historical tumor profiles, Helomics provides clinical decision support tools today to assist oncologists in individualizing cancer treatment. . . . Precision medicine is based on the idea of customizing health care, making medical decisions and selecting treatments, practices and prescriptions that are tailored to each individual patient rather than a recommended general treatment approach. A recent Acumen Research and Reporting article noted that the global precision medicine market is expected to reach total market value of approximately $84 billion by 2026 with anticipated CAGR growth of around 10% in terms of revenue between 2019 and 2026 (http://nnw.fm/tQAG2).”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Predictive Oncology (NASDAQ: POAI), through its Helomics subsidiary, is providing clinical decision support tools to support oncologists in personalizing cancer treatment. A recent article discussing the company further reads, “Through its unique patient derived (PDx) platform, which tests the drug response and biomarker profile of the patient’s own tumor, and its vast database of historical tumor profiles, Helomics provides clinical decision support tools today to assist oncologists in individualizing cancer treatment. . . . Precision medicine is based on the idea of customizing health care, making medical decisions and selecting treatments, practices and prescriptions that are tailored to each individual patient rather than a recommended general treatment approach. A recent Acumen Research and Reporting article noted that the global precision medicine market is expected to reach total market value of approximately $84 billion by 2026 with anticipated CAGR growth of around 10% in terms of revenue between 2019 and 2026 (http://nnw.fm/tQAG2).”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)
